The US Food and Drug Administration (FDA) has rolled out a new framework to spur development of new therapies for rare diseases, marking the latest initiative carried out by the Trump administration for the group of disorders.
In a notice via the Department of Health and Human Services (HHS), the FDA said the new scheme – dubbed the Rare Disease Framework Initiative – will help “reimagine” development of drugs and biologics for rare diseases.
While the rare disease landscape has seen notable successes in recent decades due to advances in technologies such as gene therapies and disease modelling, there is still a significant gap in approved treatments. According to the HHS, only 5% of rare conditions have an approved treatment.
To spur therapies to market, the FDA outlined several actions it has committed to under the new framework. The agency will provide clearer regulatory decision-making through tailored guidance, improve patient centricity, and better utilise external expertise. The FDA will also apply risk-based approaches, champion use of cutting-edge science, and pool resources and knowledge.
The Initiative is led by the FDA’s Rare Disease Innovation Hub, partnering with the Office of the Commissioner, the Center for Biologics Evaluation and Research (CBER), and the Center for Drug Evaluation and Research (CDER).
The Hub’s director, Amy Comstock Rick, said: “Patients with rare diseases and their families deserve a regulatory process that addresses the uniqueness of each of their conditions while maintaining the FDA’s rigorous standards.
“A bold vision to reimagine the regulatory framework for rare disease drug development that builds on key learnings and milestones is necessary to meet this moment. This new framework will enhance consistency and predictability for both sponsors and for patients.”
Acting FDA commissioner Kyle Diamantas said: “We will remove unnecessary barriers, embrace cutting-edge science, and accelerate promising treatments while upholding FDA’s rigorous standards.”
The National Organization for Rare Disorders (NORD) praised the new framework in a statement, saying the change is an “important and welcome step forward for the rare disease community”.
“What makes this initiative especially important is the opportunity to move beyond case-by-case regulatory accommodations toward a framework designed around the scientific realities of rare diseases,” the non-profit added.
The Rare Foundation, also a non-profit, described the news as “an extraordinary inflection point for the rare disease community.”
US government’s rare disease spotlight
The rollout of the framework marks a continuation of focus on the rare disease space from the Trump administration. In his first term, the President heavily criticised the FDA and its “slow and burdensome” process for bringing innovative therapies to market. Since assuming his second stint at the White House, Trump has overseen several modifications to rare disease regulation via HHS.
In September 2025, the Rare Disease Evidence Principles (RDEP) guidance was introduced to permit certain therapy approvals under one well-controlled clinical study. The Plausible Mechanism Framework shortly followed in November 2025, providing a new pathway to bring ground-breaking personalised therapies to market bypassing traditional requirements, though this still operates as a draft guidance framework.
Then in February 2026, the FDA issued further guidance on accelerating the development of personalised therapies for ultra-rare diseases, specifically highlighting gene-editing and RNA-based approaches.
February also saw the return of the rare paediatric disease priority review voucher (PRV) programme after a lengthy period in legislative limbo. The scheme, which was reinstated via a wider spending bill signed by Trump, acts as a significant incentive for rare disease drug development. Biotechs and rare disease charities have frequently called the PRV programme a vital financial lifeline.
